Here John is talking about Progenza as a technology platform - he mentions the distinct possibility of there being two separate licensees in Japan for separate indications to which Progenza can be applied, and using that multiple licensee model to roll out into other markets.
If this is the case, a lot of value will be generated, well above the current market cap.
